An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Philip Morris International Inc. Presents at 2022 Barclays Global Consumer Staples Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Philip Morris International Inc. (NYSE: PM) CFO Emmanuel Babeau will present at the Barclays Global Consumer Staples Conference in Boston today at 1:30 p.m. ET. The event will be available via live webcast and on the PMI Investor Relations App. PMI is committed to delivering a smoke-free future, having invested over USD 9 billion since 2008 in smoke-free product development. By June 2022, approximately 13.2 million adults globally had switched to PMI's IQOS, which is marketed as a Modified Risk Tobacco Product by the FDA, available in 70 markets excluding Russia and Ukraine.
Positive
PMI has invested over USD 9 billion since 2008 in smoke-free product development.
As of June 30, 2022, approximately 13.2 million adults have switched to IQOS.
IQOS has received FDA authorization as a Modified Risk Tobacco Product.
Negative
None.
NEW YORK--(BUSINESS WIRE)--
Regulatory News:
Philip Morris International Inc.’s (PMI) (NYSE: PM) Chief Financial Officer, Emmanuel Babeau, will address investors today at the Barclays Global Consumer Staples Conference in Boston.
The event will be webcast live in listen-only mode, beginning at approximately 1:30 p.m. ET, at www.pmi.com/2022barclays and on the PMI Investor Relations Mobile Application (available here). Presentation slides will also be available on the same site and the App.
An archived copy of the webcast will be available until 5:00 p.m. ET on Wednesday, October 5, 2022, also at www.pmi.com/2022barclays.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the U.S. Since 2008, PMI has invested more than USD 9 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. The U.S. Food and Drug Administration (FDA) has authorized the marketing of versions of PMI’s IQOS Platform 1 devices and consumables as a Modified Risk Tobacco Products (MRTPs), finding that an exposure modification orders for these products are appropriate to promote the public health. As of June 30, 2022, excluding Russia and Ukraine, PMI's smoke-free products are available for sale in 70 markets, and PMI estimates that approximately 13.2 million adults around the world had already switched to IQOS and stopped smoking. With a strong foundation and significant expertise in life sciences, in February 2021 PMI announced its ambition to expand into wellness and healthcare areas and deliver innovative products and solutions that aim to address unmet consumer and patient needs. For more information, please visit www.pmi.com and www.pmiscience.com.
